Location:
2751 Fort Amanda Road Lima, OH 45805
Phone:
567-529-9000
Fax:
567-529-9001
Working Hours:
Monday - Friday: 8.00am - 05.00pm

Patient Portal

Request An Appointment
Request An Appointment

Denosumab [Xgeva, Prolia] – (RANK Ligand Inhibitor)

  • Home
  • Urologic Cancers
  • Denosumab [Xgeva, Prolia] – (RANK Ligand Inhibitor)

As a Center of Excellence, Crossroads Urology combines advanced technology with evidence-based protocols to deliver the highest standard of specialized care for our patients.

Call Us when you Need Help!
24/7 Support: +1 567-529-9000
Denosumab [Xgeva, Prolia] – (RANK Ligand Inhibitor)

Introduction

Denosumab, sold under the trade names Xgeva and Prolia, is a RANK ligand inhibitor used to treat bone-related complications in cancer patients and bone loss conditions. It is particularly beneficial for patients with advanced prostate cancer that has metastasized to the bone or those undergoing androgen deprivation therapy (ADT), which can cause bone density loss.

Purpose

  • Xgeva: Prevents skeletal-related events (SREs) in patients with bone metastases from solid tumors, including prostate cancer.
  • Prolia: Treats bone loss in men receiving ADT for non-metastatic prostate cancer.
  • Reduces the risk of fractures and bone complications.

How It Works

Denosumab inhibits RANK ligand, a protein that activates osteoclasts (cells responsible for bone breakdown). By blocking RANK ligand, Denosumab slows bone resorption, preserving bone density and strength while reducing the risk of fractures and skeletal complications.

Usage

  • Xgeva: Administered as a subcutaneous injection every four weeks for bone metastases.
  • Prolia: Administered as a subcutaneous injection every six months for bone loss prevention.
  • Patients should take calcium and vitamin D supplements during treatment to support bone health.

Considerations

  • Common side effects include fatigue, musculoskeletal pain, and mild injection site reactions.
  • Rare but serious side effects include hypocalcemia (low calcium levels) and osteonecrosis of the jaw; patients should undergo a dental evaluation before starting therapy.
  • Regular monitoring of calcium levels and overall bone health is recommended.

At Crossroads Urology

At Crossroads Urology, Denosumab is an essential part of managing bone health in patients with advanced prostate cancer. Our providers ensure safe administration and ongoing monitoring to maximize benefits while minimizing risks.

Conclusion

Denosumab [Xgeva, Prolia] is a vital tool for preserving bone health in patients with prostate cancer, reducing the risk of fractures and other complications. Contact Crossroads Urology today to learn more about this treatment and how it can benefit you.